addit pharmedium detail expect major today call focus
pharmedium busi manag note ep guidanc assum
nomin contribut pharmedium memphi facil importantli expect
facil return oper re-open phase manner
expect facil fulli oper recal manag
previous suggest pharmedium neg impact ebit could
mln higher number conjunct today updat
howev remain unclear much prior mln view tie lost
volum vs remedi cost compani note inde remedi
cost incur dec well detail given march expect
incur remedi cost also exclud
adjust ep ep neg impact lengthier
memphi closur manag said account ebit guid
reduct today manag indic posit custom pharmedium
larg bring busi in-hous vs move competitor
make easier potenti recaptur lost volum memphi re-open
drug price commentari detail manag note gener deflat
stabl still guid deflat take better trend
flu like drug distributor stock trade today also
comment brand inflat better expect expect
less price increas june/juli period regard segment
soft relat fusion platform migrat lash well sluggish
product anim side vet distribut busi due weather final
manag clarifi exclud impact new brazil hd smith busi
oper expens growth would in-lin initi expect given
result rais ep lower ep
pt base price-to-earnings ep estim
quarterli annual ep usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight gain
share via largest custom walgreen
compani continu face headwind throughout
relat gener price deflat
believ persist hamper ep growth
upsid case see modest multipl expans
gener price deflat come better fear
would lead multipl ep
downsid case see continu persist
gener deflat continu problem
pharmedium bring compani peer
group
 servic profit profit profit marginsdown bpstax changeshar repurchaseoffset dilutionoffset dilutionoffset dilutionoffset milgener new genericscontribut new genericscontribut new genericscontribut new genericssimilar prior yearsimilar prior yearsimilar prior yearsimilar prior yearno signific contribut biosimsno signific contribut biosimsno signific contribut biosimsno signific contribut biosimshd smith acquisit includedhd smith acquisit includedbottom end ep guidanc barclay corp
amerisourcebergen revenu profit model
 annual revenu model mil abcabcabcabcabcabcrevenu revenueabdc drug specialti distribut global commerci servic anim growthabdc drug specialti distribut global commerci servic anim total revsabdc drug specialti distribut global commerci servic anim annual gross profit mil abcabcabcabcabcabcgross profit gross profit formula pharma distribut strateg global global commerci servic anim incom gross growthpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmnmtotal gross gp margin press releas pharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmnmtotal gross profit annual oper profit mil abcabcabcabcabcabcoper profit ebit ebitpharma distribut strateg global global commerci servic anim incom growthpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmnmtotal ebit ebit marginpharma distribut strateg global global commerci servic anim incom ebit barclay corp
 quarterli incom statement mil ep ep ep ep ep distribut sell oper addback check excl intang asset ens rate check ep fulli dilut share growth distribut sell per barclay corp
steve valiquett herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
author contribut research report research analyst unless otherwis indic
public date top report reflect local time report produc may differ releas date provid
gmt
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis barclay research depart
oper independ absa research depart absa research produc absa bank limit act corpor
invest bank divis part barclay africa group limit affili invest bank barclay bank plc elig
client may receiv research report research depart may reach differ conclus may contain differ
conflict forecast recommend trade idea
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
